Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MEDI-563 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | MEDI-563 |
| 2 | EXPERIMENTAL | MEDI-563 |
| 4 | PLACEBO_COMPARATOR | Placebo |
| 5 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| MEDI-563 | DRUG | 1.0 mg/kg IV: MEDI-563 |
| Placebo Comp. | OTHER | Placebo SC |
| Placebo | OTHER | Placebo as a single IV infusion (Certain number of subjects) |
Inclusion Criteria: * Male or female adults, 18 through 65 years of age at time of randomization; * Written informed consent obtained from the subject prior to beginning study procedures or receipt of any study medication; * Previously documented diagnosis of asthma of ≥ 1 year duration, based on e...
MEDI-563 is an investigational monoclonal antibody being developed for the treatment of asthma. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in clinical trials.
MEDI-563 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The drug is in Phase 1 clinical development for the treatment of asthma.
MEDI-563 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. Two Phase 1 clinical trials have been completed, but the drug is not yet approved for any use.
MEDI-563 has been studied in two completed Phase 1 clinical trials. The first trial, NCT00512486, was a sequential dose-escalation study in subjects with mild asthma, enrolling 42 participants. The second trial, NCT00659659, evaluated safety, tolerability, and effects in adults with asthma, enrolling 27 participants.
MEDI-563 is an alternative name for benralizumab, a monoclonal antibody being developed by AstraZeneca for the treatment of asthma. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.